Fox A - Search Results

1

Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ. Esser R, et al. Among authors: fox a. Br J Pharmacol. 2005 Feb;144(4):538-50. doi: 10.1038/sj.bjp.0706078. Br J Pharmacol. 2005. PMID: 15655513 Free PMC article.

2

Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.

Fox A, Medhurst S, Courade JP, Glatt M, Dawson J, Urban L, Bevan S, Gonzalez I. Fox A, et al. Pain. 2004 Jan;107(1-2):33-40. doi: 10.1016/j.pain.2003.09.003. Pain. 2004. PMID: 14715386

3

The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain.

Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P. Walker KM, et al. J Pharmacol Exp Ther. 2003 Jan;304(1):56-62. doi: 10.1124/jpet.102.042010. J Pharmacol Exp Ther. 2003. PMID: 12490575

4

Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat.

Fox A, Eastwood C, Gentry C, Manning D, Urban L. Fox A, et al. Pain. 1999 Jun;81(3):307-316. doi: 10.1016/S0304-3959(99)00024-X. Pain. 1999. PMID: 10431718

5

Animal models for pain research.

Walker K, Fox AJ, Urban LA. Walker K, et al. Among authors: fox aj. Mol Med Today. 1999 Jul;5(7):319-21. doi: 10.1016/s1357-4310(99)01493-8. Mol Med Today. 1999. PMID: 10498437 Review. No abstract available.

6

Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig.

Campbell EA, Gentry C, Patel S, Kidd B, Cruwys S, Fox AJ, Urban L. Campbell EA, et al. Among authors: fox aj. Pain. 2000 Sep;87(3):253-263. doi: 10.1016/S0304-3959(00)00288-8. Pain. 2000. PMID: 10963905

7

Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor.

Fox A, Kaur S, Li B, Panesar M, Saha U, Davis C, Dragoni I, Colley S, Ritchie T, Bevan S, Burgess G, McIntyre P. Fox A, et al. Br J Pharmacol. 2005 Apr;144(7):889-99. doi: 10.1038/sj.bjp.0706139. Br J Pharmacol. 2005. PMID: 15685199 Free PMC article.

8

Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.

Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, McNair K, Kesingland A, Green J, Chan O, Fox AJ, Urban LA. Walker K, et al. Among authors: fox aj. Pain. 2002 Dec;100(3):219-229. doi: 10.1016/S0304-3959(02)00040-4. Pain. 2002. PMID: 12467993

9

NK1 receptor antagonists--are they really without effect in the pain clinic?

Urban LA, Fox AJ. Urban LA, et al. Among authors: fox aj. Trends Pharmacol Sci. 2000 Dec;21(12):462-4; author reply 465. doi: 10.1016/s0165-6147(00)01578-9. Trends Pharmacol Sci. 2000. PMID: 11229417 No abstract available.

10

Excitatory effects of galanin in the spinal cord of intact, anaesthetized rats.

Reeve AJ, Walker K, Urban L, Fox A. Reeve AJ, et al. Among authors: fox a. Neurosci Lett. 2000 Dec 1;295(1-2):25-8. doi: 10.1016/s0304-3940(00)01576-7. Neurosci Lett. 2000. PMID: 11078928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,887 results

Search Page

Filters